Symbols / LFCR Stock $5.23 +0.00% Lifecore Biomedical, Inc.
LFCR (Stock) Chart
About
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Stock Fundamentals
Scroll to Statements| Market Cap | 196.01M | Enterprise Value | 368.08M | Income | -34.50M | Sales | 129.46M | Book/sh | -0.38 | Cash/sh | 0.47 |
| Dividend Yield | — | Payout | 0.00% | Employees | 400 | IPO | — | P/E | — | Forward P/E | -6.30 |
| PEG | 2.66 | P/S | 1.51 | P/B | -13.80 | P/C | — | EV/EBITDA | 44.66 | EV/Sales | 2.84 |
| Quick Ratio | 2.18 | Current Ratio | 3.49 | Debt/Eq | 414.80 | LT Debt/Eq | — | EPS (ttm) | -1.27 | EPS next Y | -0.83 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-05 | ROA | — | ROE | — | ROIC | — |
| Gross Margin | 31.37% | Oper. Margin | 8.18% | Profit Margin | -23.78% | Shs Outstand | 37.48M | Shs Float | 19.84M | Short Float | 12.08% |
| Short Ratio | 5.49 | Short Interest | — | 52W High | 8.98 | 52W Low | 3.63 | Beta | 0.88 | Avg Volume | 315.43K |
| Volume | 158.19K | Target Price | $6.50 | Recom | None | Prev Close | $5.23 | Price | $5.23 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | Barrington Research | Outperform → Outperform | $6 |
| 2026-03-24 | main | Barrington Research | Outperform → Outperform | $6 |
| 2026-03-17 | up | Barrington Research | Market Perform → Outperform | $6 |
| 2025-09-04 | init | Keybanc | — → Sector Weight | — |
| 2025-05-21 | init | William Blair | — → Outperform | — |
| 2025-01-03 | reit | Stephens & Co. | Equal-Weight → Equal-Weight | $6 |
| 2024-11-22 | main | Craig-Hallum | Buy → Buy | $10 |
| 2024-09-05 | init | Craig-Hallum | — → Buy | $8 |
| 2024-08-28 | down | Barrington Research | Outperform → Market Perform | — |
| 2023-09-01 | main | Barrington Research | Outperform → Outperform | $10 |
| 2023-09-01 | main | Stephens & Co. | Equal-Weight → Equal-Weight | $9 |
| 2023-06-02 | main | Barrington Research | Outperform → Outperform | $11 |
| 2023-05-24 | main | Barrington Research | Outperform → Outperform | $10 |
| 2023-03-21 | main | Barrington Research | — → Outperform | $8 |
| 2023-03-20 | main | Barrington Research | — → Outperform | $8 |
| 2023-03-20 | down | Stephens & Co. | Overweight → Equal-Weight | $2 |
| 2023-03-17 | reit | Stephens & Co. | — → Overweight | $11 |
- New Lifecore hire gets 5,000 stock units that vest in 3 years - Stock Titan Wed, 22 Apr 2026 20
- Here’s Why Lifecore Biomedical Inc (LFCR) Declined 22% at the End of Q3 - Yahoo Finance hu, 30 Oct 2025 07
- Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives - simplywall.st Mon, 16 Mar 2026 07
- Will Lifecore Biomedical (LFCR) Stock Rise in 2026 | Price at $4.88, Up 2.74% - Expert Verified Trades - Cổng thông tin điện tử tỉnh Lào Cai Mon, 13 Apr 2026 07
- Lifecore Biomedical: The Turnaround Is Just Getting Started (NASDAQ:LFCR) - Seeking Alpha hu, 01 Jan 2026 08
- The Technical Signals Behind (LFCR) That Institutions Follow - Stock Traders Daily Wed, 15 Apr 2026 21
- Lifecore Biomedical Reports Financial Results for the - GlobeNewswire Mon, 16 Mar 2026 07
- Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times Wed, 22 Apr 2026 20
- Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN Sun, 12 Apr 2026 20
- Lifecore heads to San Francisco biomanufacturing summit on April 14 - Stock Titan Wed, 08 Apr 2026 07
- Lifecore Biomedical: A Disconnect Between Share Price And Business Progress (LFCR) - Seeking Alpha Sun, 09 Nov 2025 08
- Hedge funds investors in Lifecore Biomedical, Inc. (NASDAQ:LFCR) lost 14% last week but have reaped the benefits of longer-term growth - simplywall.st Fri, 26 Sep 2025 07
- Lifecore Biomedical: Wins Should Blow Previous 'New Business' Estimates Out Of The Water (undefined:LFCR) - Seeking Alpha Wed, 14 Jan 2026 08
- Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025 - Stock Titan Mon, 16 Mar 2026 07
- A marketed drug is set to switch manufacturers in Lifecore's 2-deal win - Stock Titan hu, 26 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
128.87
+0.47%
|
128.26
+24.20%
|
103.27
-7.19%
|
111.27
|
| Operating Revenue |
|
128.87
+0.47%
|
128.26
+24.20%
|
103.27
-7.19%
|
111.27
|
| Cost Of Revenue |
|
88.57
+2.50%
|
86.41
+14.78%
|
75.28
+4.27%
|
72.20
|
| Reconciled Cost Of Revenue |
|
88.57
+2.50%
|
86.41
+14.78%
|
75.28
+4.27%
|
72.20
|
| Gross Profit |
|
40.30
-3.71%
|
41.85
+49.54%
|
27.98
-28.36%
|
39.07
|
| Operating Expense |
|
52.30
+6.66%
|
49.04
+2.79%
|
47.70
+12.25%
|
42.50
|
| Research And Development |
|
8.26
-3.70%
|
8.57
-1.84%
|
8.74
+11.44%
|
7.84
|
| Selling General And Administration |
|
44.05
+8.86%
|
40.46
+3.83%
|
38.97
+12.44%
|
34.66
|
| Total Expenses |
|
140.87
+4.00%
|
135.45
+10.13%
|
122.99
+7.22%
|
114.70
|
| Operating Income |
|
-12.01
-67.03%
|
-7.19
+63.55%
|
-19.72
-474.59%
|
-3.43
|
| Total Operating Income As Reported |
|
-17.25
-94.99%
|
-8.84
+59.42%
|
-21.80
-84.85%
|
-11.79
|
| EBITDA |
|
-8.48
-123.81%
|
35.62
+207.37%
|
-33.17
-358.25%
|
12.84
|
| Normalized EBITDA |
|
-3.65
-63.78%
|
-2.23
+69.70%
|
-7.35
-134.68%
|
21.20
|
| Reconciled Depreciation |
|
8.03
+0.92%
|
7.95
-39.64%
|
13.18
-27.04%
|
18.06
|
| EBIT |
|
-16.51
-159.67%
|
27.66
+159.68%
|
-46.35
-788.38%
|
-5.22
|
| Total Unusual Items |
|
-4.83
-112.76%
|
37.84
+246.59%
|
-25.82
-208.85%
|
-8.36
|
| Total Unusual Items Excluding Goodwill |
|
-4.83
-112.76%
|
37.84
+246.59%
|
-25.82
-208.85%
|
-8.36
|
| Special Income Charges |
|
-5.24
-216.36%
|
-1.66
+93.59%
|
-25.82
-208.85%
|
-8.36
|
| Other Special Charges |
|
—
|
—
|
23.74
|
—
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
28.73
|
| Restructuring And Mergern Acquisition |
|
-1.75
-205.50%
|
1.66
-60.42%
|
4.18
-49.95%
|
8.36
|
| Net Income |
|
-38.72
-422.29%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Pretax Income |
|
-38.67
-506.50%
|
9.51
+114.88%
|
-63.93
-209.02%
|
-20.69
|
| Net Non Operating Interest Income Expense |
|
-21.84
-20.70%
|
-18.09
-2.90%
|
-17.58
-13.65%
|
-15.47
|
| Interest Expense Non Operating |
|
22.17
+22.15%
|
18.15
+3.23%
|
17.58
+13.65%
|
15.47
|
| Net Interest Income |
|
-21.84
-20.70%
|
-18.09
-2.90%
|
-17.58
-13.65%
|
-15.47
|
| Interest Expense |
|
22.17
+22.15%
|
18.15
+3.23%
|
17.58
+13.65%
|
15.47
|
| Interest Income Non Operating |
|
0.33
+474.14%
|
0.06
-14.71%
|
0.07
-16.05%
|
0.08
|
| Interest Income |
|
0.33
+474.14%
|
0.06
-14.71%
|
0.07
-16.05%
|
0.08
|
| Other Income Expense |
|
-4.83
-113.89%
|
34.79
+230.66%
|
-26.63
-1391.71%
|
-1.78
|
| Other Non Operating Income Expenses |
|
-0.00
+99.90%
|
-3.05
-276.79%
|
-0.81
-112.32%
|
6.57
|
| Gain On Sale Of Security |
|
0.41
-98.96%
|
39.50
|
—
|
—
|
| Gain On Sale Of Business |
|
—
|
0.00
-100.00%
|
2.11
|
0.00
|
| Tax Provision |
|
0.04
-76.50%
|
0.18
-40.58%
|
0.31
+105.91%
|
-5.21
|
| Tax Rate For Calcs |
|
0.00
+991.76%
|
0.00
-90.84%
|
0.00
-16.63%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.01
-239.34%
|
0.73
+113.43%
|
-5.42
-157.48%
|
-2.11
|
| Net Income Including Noncontrolling Interests |
|
-38.72
-422.29%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Net Income From Continuing Operation Net Minority Interest |
|
-38.72
-514.93%
|
9.33
+114.53%
|
-64.24
-315.07%
|
-15.48
|
| Net Income From Continuing And Discontinued Operation |
|
-38.72
-422.29%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Net Income Continuous Operations |
|
-38.72
-514.93%
|
9.33
+114.53%
|
-64.24
-315.07%
|
-15.48
|
| Net Income Discontinuous Operations |
|
0.00
-100.00%
|
2.68
+107.59%
|
-35.33
+65.11%
|
-101.24
|
| Normalized Income |
|
-34.90
-25.61%
|
-27.79
+36.62%
|
-43.84
-375.36%
|
-9.22
|
| Net Income Common Stockholders |
|
-44.36
-469.26%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Otherunder Preferred Stock Dividend |
|
2.32
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-1.27
-496.88%
|
0.32
+109.38%
|
-3.41
-3.33%
|
-3.30
|
| Basic EPS |
|
-1.27
-417.50%
|
0.40
+111.73%
|
-3.41
-3.50%
|
-3.29
|
| Basic Average Shares |
|
34.82
+14.26%
|
30.47
+1.69%
|
29.97
+1.54%
|
29.51
|
| Diluted Average Shares |
|
34.82
-5.02%
|
36.66
+22.32%
|
29.97
+1.54%
|
29.51
|
| Diluted NI Availto Com Stockholders |
|
-44.36
-469.26%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Gain On Sale Of PPE |
|
-6.99
|
0.00
|
—
|
—
|
| Preferred Stock Dividends |
|
3.32
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 |
|---|---|---|---|---|---|
| Total Assets |
|
232.18
-2.99%
|
239.34
-5.76%
|
253.96
+0.16%
|
253.54
|
| Current Assets |
|
82.29
-3.95%
|
85.68
+5.73%
|
81.03
-13.68%
|
93.88
|
| Cash Cash Equivalents And Short Term Investments |
|
17.47
+111.36%
|
8.27
-2.33%
|
8.46
-55.68%
|
19.09
|
| Cash And Cash Equivalents |
|
17.47
+111.36%
|
8.27
-2.33%
|
8.46
-55.68%
|
19.09
|
| Receivables |
|
33.82
-22.56%
|
43.67
+40.17%
|
31.15
+7.34%
|
29.02
|
| Accounts Receivable |
|
26.16
-8.81%
|
28.69
+5.92%
|
27.08
-6.68%
|
29.02
|
| Gross Accounts Receivable |
|
27.21
-9.43%
|
30.04
+8.07%
|
27.80
-5.81%
|
29.51
|
| Allowance For Doubtful Accounts Receivable |
|
-1.04
+22.72%
|
-1.35
-90.01%
|
-0.71
-46.60%
|
-0.48
|
| Other Receivables |
|
7.66
+9.69%
|
6.98
+71.52%
|
4.07
|
—
|
| Inventory |
|
29.09
-9.93%
|
32.29
-19.23%
|
39.98
-2.11%
|
40.84
|
| Raw Materials |
|
10.09
-0.76%
|
10.17
-22.61%
|
13.14
-25.91%
|
17.73
|
| Work In Process |
|
7.15
-18.24%
|
8.74
-26.62%
|
11.91
+15.13%
|
10.35
|
| Finished Goods |
|
11.85
-11.47%
|
13.38
-10.35%
|
14.92
+13.57%
|
13.14
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Assets Held For Sale Current |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
1.92
+32.12%
|
1.45
+1.04%
|
1.44
-70.75%
|
4.92
|
| Total Non Current Assets |
|
149.88
-2.46%
|
153.66
-11.14%
|
172.93
+8.30%
|
159.67
|
| Net PPE |
|
127.30
-1.32%
|
129.01
-13.51%
|
149.16
+7.57%
|
138.67
|
| Gross PPE |
|
186.46
+0.02%
|
186.42
-6.56%
|
199.50
+1.95%
|
195.68
|
| Accumulated Depreciation |
|
-59.16
-3.04%
|
-57.41
-14.06%
|
-50.33
+11.70%
|
-57.01
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
3.49
-6.63%
|
3.74
+0.00%
|
3.74
+0.00%
|
3.74
|
| Buildings And Improvements |
|
82.02
+28.70%
|
63.73
+1.36%
|
62.87
+3.60%
|
60.69
|
| Machinery Furniture Equipment |
|
91.41
+28.41%
|
71.19
+0.36%
|
70.93
-8.31%
|
77.36
|
| Construction In Progress |
|
9.54
-80.03%
|
47.76
-22.91%
|
61.95
+35.90%
|
45.59
|
| Other Properties |
|
—
|
—
|
2.44
-42.97%
|
4.28
|
| Leases |
|
—
|
—
|
0.00
-100.00%
|
4.02
|
| Goodwill And Other Intangible Assets |
|
13.88
+0.00%
|
13.88
+0.00%
|
13.88
-23.23%
|
18.08
|
| Goodwill |
|
13.88
+0.00%
|
13.88
+0.00%
|
13.88
+0.00%
|
13.88
|
| Other Intangible Assets |
|
—
|
4.20
+0.00%
|
4.20
+0.00%
|
4.20
|
| Investments And Advances |
|
—
|
—
|
—
|
—
|
| Other Investments |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
8.70
-19.28%
|
10.78
+9.08%
|
9.88
+238.74%
|
2.92
|
| Total Liabilities Net Minority Interest |
|
246.38
+3.52%
|
238.01
-1.91%
|
242.65
-5.87%
|
257.77
|
| Current Liabilities |
|
23.57
-21.89%
|
30.18
-22.37%
|
38.87
-1.06%
|
39.29
|
| Payables And Accrued Expenses |
|
7.54
-49.56%
|
14.95
-38.06%
|
24.14
-17.45%
|
29.24
|
| Payables |
|
5.84
-54.09%
|
12.72
-35.78%
|
19.80
-10.37%
|
22.10
|
| Accounts Payable |
|
5.84
-28.97%
|
8.22
-49.68%
|
16.33
-26.08%
|
22.10
|
| Other Payable |
|
—
|
4.50
+29.62%
|
3.47
|
—
|
| Current Accrued Expenses |
|
1.70
-23.75%
|
2.23
-48.46%
|
4.33
-39.36%
|
7.14
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.55
-25.98%
|
6.14
-0.34%
|
6.17
+48.73%
|
4.14
|
| Current Debt And Capital Lease Obligation |
|
1.33
-65.32%
|
3.82
-22.05%
|
4.91
+165.19%
|
1.85
|
| Current Debt |
|
0.77
-77.51%
|
3.44
+264.48%
|
0.94
+62.59%
|
0.58
|
| Other Current Borrowings |
|
0.77
-77.51%
|
3.44
+264.48%
|
0.94
+62.59%
|
0.58
|
| Current Capital Lease Obligation |
|
0.55
+42.89%
|
0.39
-90.23%
|
3.96
+212.05%
|
1.27
|
| Current Deferred Liabilities |
|
8.66
+153.59%
|
3.42
+61.62%
|
2.11
-47.89%
|
4.05
|
| Current Deferred Revenue |
|
8.66
+153.59%
|
3.42
+61.62%
|
2.11
-47.89%
|
4.05
|
| Other Current Liabilities |
|
1.50
-18.76%
|
1.84
+18.81%
|
1.55
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
222.81
+7.21%
|
207.83
+1.99%
|
203.77
-6.73%
|
218.49
|
| Liabilities Heldfor Sale Non Current |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
141.28
+11.25%
|
127.00
+2.65%
|
123.72
+11.69%
|
110.77
|
| Long Term Debt |
|
135.59
+6.76%
|
127.00
+2.65%
|
123.72
+22.42%
|
101.06
|
| Long Term Capital Lease Obligation |
|
5.69
|
—
|
4.94
-49.08%
|
9.71
|
| Non Current Deferred Liabilities |
|
—
|
—
|
5.25
+58.01%
|
3.32
|
| Non Current Deferred Revenue |
|
—
|
—
|
4.70
+59.97%
|
2.94
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
0.54
+42.89%
|
0.38
|
| Other Non Current Liabilities |
|
6.70
-31.24%
|
9.74
-19.24%
|
12.06
+6831.61%
|
0.17
|
| Preferred Securities Outside Stock Equity |
|
48.26
+4.70%
|
46.10
+8.24%
|
42.59
+8.31%
|
39.32
|
| Stockholders Equity |
|
-14.20
-1163.02%
|
1.34
-88.19%
|
11.31
+367.49%
|
-4.23
|
| Common Stock Equity |
|
-14.20
-1163.02%
|
1.34
-88.19%
|
11.31
+367.49%
|
-4.23
|
| Capital Stock |
|
0.04
+0.00%
|
0.04
+19.35%
|
0.03
+3.33%
|
0.03
|
| Common Stock |
|
0.04
+0.00%
|
0.04
+19.35%
|
0.03
+3.33%
|
0.03
|
| Share Issued |
|
37.48
+1.22%
|
37.03
+21.15%
|
30.56
+3.56%
|
29.51
|
| Ordinary Shares Number |
|
37.48
+1.22%
|
37.03
+21.15%
|
30.56
+3.56%
|
29.51
|
| Additional Paid In Capital |
|
208.96
+1.17%
|
206.54
+16.16%
|
177.81
+2.03%
|
174.28
|
| Retained Earnings |
|
-223.20
-8.75%
|
-205.24
-23.25%
|
-166.52
+6.73%
|
-178.54
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
—
|
0.00
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
-14.20
-1163.02%
|
1.34
-88.19%
|
11.31
+367.49%
|
-4.23
|
| Total Capitalization |
|
121.39
-5.41%
|
128.34
-4.97%
|
135.04
+39.45%
|
96.83
|
| Working Capital |
|
58.72
+5.80%
|
55.50
+31.64%
|
42.16
-22.76%
|
54.59
|
| Invested Capital |
|
122.16
-7.30%
|
131.77
-3.10%
|
135.98
+39.59%
|
97.42
|
| Total Debt |
|
142.61
+9.01%
|
130.82
+1.70%
|
128.63
+14.21%
|
112.62
|
| Net Debt |
|
118.89
-2.68%
|
122.17
+5.13%
|
116.21
+40.76%
|
82.55
|
| Capital Lease Obligations |
|
6.25
+1514.21%
|
0.39
-90.23%
|
3.96
-63.90%
|
10.98
|
| Net Tangible Assets |
|
-28.08
-123.86%
|
-12.54
-388.89%
|
-2.57
+88.50%
|
-22.31
|
| Tangible Book Value |
|
-28.08
-123.86%
|
-12.54
-388.89%
|
-2.57
+88.50%
|
-22.31
|
| Derivative Product Liabilities |
|
26.56
+6.29%
|
24.99
-1.61%
|
25.40
-60.86%
|
64.90
|
| Inventories Adjustments Allowances |
|
—
|
—
|
-1.42
-268.49%
|
-0.38
|
| Line Of Credit |
|
—
|
—
|
—
|
0.00
|
| Notes Receivable |
|
0.00
-100.00%
|
8.00
|
0.00
|
—
|
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-0.21
-180.16%
|
0.26
+101.47%
|
-17.44
+22.80%
|
-22.59
|
| Cash Flow From Continuing Operating Activities |
|
-0.21
-180.16%
|
0.26
+101.47%
|
-17.44
+22.80%
|
-22.59
|
| Net Income From Continuing Operations |
|
-38.72
-422.29%
|
12.01
+112.07%
|
-99.56
+14.70%
|
-116.72
|
| Depreciation Amortization Depletion |
|
8.03
+0.92%
|
7.95
-39.64%
|
13.18
-27.04%
|
18.06
|
| Depreciation |
|
8.03
+0.92%
|
7.95
-40.13%
|
13.29
-25.72%
|
17.88
|
| Depreciation And Amortization |
|
8.03
+0.92%
|
7.95
-39.64%
|
13.18
-27.04%
|
18.06
|
| Other Non Cash Items |
|
17.65
+2.22%
|
17.27
+1515.53%
|
1.07
+350.94%
|
-0.43
|
| Stock Based Compensation |
|
10.16
+63.81%
|
6.20
+71.68%
|
3.61
+38.50%
|
2.61
|
| Provisionand Write Offof Assets |
|
—
|
0.26
+61.35%
|
0.16
+1264.29%
|
-0.01
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
1.30
-98.34%
|
78.15
|
| Deferred Tax |
|
—
|
0.16
-54.34%
|
0.36
+105.23%
|
-6.83
|
| Deferred Income Tax |
|
—
|
0.16
-54.34%
|
0.36
+105.23%
|
-6.83
|
| Operating Gains Losses |
|
7.37
+118.66%
|
-39.48
-192.57%
|
42.65
+651.86%
|
5.67
|
| Gain Loss On Investment Securities |
|
-0.41
+98.96%
|
-39.50
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
7.78
+43100.00%
|
0.02
-52.63%
|
0.04
-99.29%
|
5.34
|
| Change In Working Capital |
|
-4.70
-26.93%
|
-3.70
-118.69%
|
19.79
+738.21%
|
-3.10
|
| Change In Receivables |
|
-5.17
-116.22%
|
-2.39
-122.10%
|
10.82
+276.34%
|
-6.14
|
| Changes In Account Receivables |
|
-2.26
+30.68%
|
-3.26
-130.15%
|
10.82
+276.34%
|
-6.14
|
| Change In Inventory |
|
7.69
+791.88%
|
0.86
+105.82%
|
-14.81
-579.40%
|
-2.18
|
| Change In Prepaid Assets |
|
—
|
—
|
2.16
+458.14%
|
-0.60
|
| Change In Payables And Accrued Expense |
|
-7.59
-51.09%
|
-5.02
-132.31%
|
15.55
+162.42%
|
5.92
|
| Change In Accrued Expense |
|
-5.92
-458.08%
|
1.65
+435.98%
|
-0.49
+85.61%
|
-3.42
|
| Change In Payable |
|
-1.67
+74.99%
|
-6.68
-141.63%
|
16.04
+71.66%
|
9.34
|
| Change In Account Payable |
|
-1.67
+74.99%
|
-6.68
-141.63%
|
16.04
+71.66%
|
9.34
|
| Change In Other Working Capital |
|
—
|
-0.18
-102.95%
|
6.08
+33855.56%
|
-0.02
|
| Change In Other Current Assets |
|
0.38
-86.76%
|
2.85
+32.37%
|
2.16
+412.92%
|
-0.69
|
| Investing Cash Flow |
|
-6.42
+65.13%
|
-18.39
-282.35%
|
-4.81
-106.02%
|
79.96
|
| Cash Flow From Continuing Investing Activities |
|
-6.42
+65.13%
|
-18.39
-282.35%
|
-4.81
-106.02%
|
79.96
|
| Net PPE Purchase And Sale |
|
-6.42
+65.13%
|
-18.39
+14.37%
|
-21.48
+25.41%
|
-28.80
|
| Purchase Of PPE |
|
-13.41
+27.07%
|
-18.39
+14.37%
|
-21.48
+28.25%
|
-29.94
|
| Sale Of PPE |
|
7.00
|
0.00
|
0.00
-100.00%
|
1.14
|
| Capital Expenditure |
|
-13.41
+27.07%
|
-18.39
+14.37%
|
-21.48
+28.25%
|
-29.94
|
| Net Investment Purchase And Sale |
|
—
|
0.00
|
0.00
-100.00%
|
45.10
|
| Sale Of Investment |
|
—
|
0.00
|
0.00
-100.00%
|
45.10
|
| Net Business Purchase And Sale |
|
—
|
0.00
-100.00%
|
16.67
-77.32%
|
73.50
|
| Purchase Of Business |
|
—
|
—
|
0.00
+100.00%
|
-9.84
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
-100.00%
|
18.87
+5517.26%
|
0.34
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-9.84
|
| Financing Cash Flow |
|
6.42
-14.45%
|
7.51
-81.09%
|
39.70
+169.62%
|
-57.02
|
| Cash Flow From Continuing Financing Activities |
|
6.42
-14.45%
|
7.51
-81.09%
|
39.70
+169.62%
|
-57.02
|
| Net Issuance Payments Of Debt |
|
-14.79
-613.22%
|
2.88
-7.63%
|
3.12
+105.63%
|
-55.41
|
| Issuance Of Debt |
|
130.97
-12.45%
|
149.59
-17.56%
|
181.45
+141.58%
|
75.11
|
| Repayment Of Debt |
|
-145.76
+0.64%
|
-146.70
+17.73%
|
-178.33
-36.63%
|
-130.52
|
| Long Term Debt Issuance |
|
130.97
-12.45%
|
149.59
-17.56%
|
181.45
+141.58%
|
75.11
|
| Long Term Debt Payments |
|
-145.76
+0.64%
|
-146.70
+17.73%
|
-178.33
-36.63%
|
-130.52
|
| Net Long Term Debt Issuance |
|
-14.79
-613.22%
|
2.88
-7.63%
|
3.12
+105.63%
|
-55.41
|
| Short Term Debt Issuance |
|
—
|
—
|
31.45
-42.93%
|
55.11
|
| Short Term Debt Payments |
|
—
|
—
|
-54.64
-23.87%
|
-44.11
|
| Net Short Term Debt Issuance |
|
—
|
—
|
-54.64
-23.87%
|
-44.11
|
| Net Common Stock Issuance |
|
23.85
|
0.00
-100.00%
|
4.82
|
0.00
|
| Proceeds From Stock Option Exercised |
|
-1.27
-735.53%
|
-0.15
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-1.36
-128.56%
|
4.78
+175.57%
|
-6.32
-292.80%
|
-1.61
|
| Changes In Cash |
|
-0.20
+98.15%
|
-10.63
-160.92%
|
17.45
+4913.79%
|
0.35
|
| Beginning Cash Position |
|
8.46
-55.68%
|
19.09
+1061.96%
|
1.64
+26.87%
|
1.29
|
| End Cash Position |
|
8.27
-2.33%
|
8.46
-55.68%
|
19.09
+1061.96%
|
1.64
|
| Free Cash Flow |
|
-13.62
+24.90%
|
-18.14
+53.40%
|
-38.92
+25.91%
|
-52.53
|
| Interest Paid Supplemental Data |
|
1.91
-30.15%
|
2.73
-91.20%
|
31.02
+83.70%
|
16.89
|
| Income Tax Paid Supplemental Data |
|
0.05
-36.11%
|
0.07
+213.04%
|
0.02
-94.78%
|
0.44
|
| Common Stock Issuance |
|
23.85
|
0.00
-100.00%
|
4.82
|
0.00
|
| Issuance Of Capital Stock |
|
23.85
|
0.00
-100.00%
|
42.90
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
38.08
|
0.00
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
38.08
|
0.00
|
| Sale Of Business |
|
—
|
0.00
-100.00%
|
16.67
-77.32%
|
73.50
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-16 View
- 8-K2026-03-16 View
- 8-K2026-03-05 View
- 42026-03-02 View
- 8-K2026-01-16 View
- 8-K2025-11-17 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-10-31 View
- 8-K2025-09-26 View
- 42025-09-04 View
- 8-K2025-08-18 View
- 8-K2025-08-12 View
- 10-K2025-08-07 View
- 8-K2025-08-07 View
- 8-K2025-07-18 View
- 42025-07-17 View
- 42025-07-17 View
- 42025-07-17 View
- 42025-07-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|